Navigation Links
bite in Biological Technology

Micromet Closes $80.5 Million Public Offering of Common Stock

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... from the European Medicines Agency (EMEA) for bite antibody blinatumomab (MT103) for acute ... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ...

Micromet Announces Pricing of Public Offering of Common Stock

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet Announces Public Offering of Common Stock

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet Added to Russell 3000 Index

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... with non-Hodgkin's lymphoma. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... with non-Hodgkin's lymphoma. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

... with lung or gastrointestinal cancer. bite antibodies such as MT110 represent a novel class ... (3). The data presented at AACR show that the bite antibody MT110 can direct T cells to eliminate ... from a study of MT110 in mice showed that the bite antibody eliminated even large numbers of ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... demonstrating the potent anti-tumor activity of a bite antibody binding to carcinoembryonic antigen ... as target antigen for development of a new bite antibody program because CEA is widely expressed ... antibody efficacy. The new study shows that novel bite antibodies have strong activity against ...

Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... with non-Hodgkin's lymphoma. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

... of Sir Walter Bodmer and Bernard Fox to its bite antibody advisory panel. Other members of the ... in key areas relevant for the development of new bite antibodies for the treatment of cancer." ... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ...

Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research

... human colon cancer cells by T cell-engaging bite antibodies derived from anti-EGFR antibodies ... colon cancer stem cells by EpCAM/CD3-bispecific bite antibody MT110. AACR Annual Meeting 2009, ... redirected target cell lysis by T cell-engaging bite antibody MT110. AACR Annual Meeting 2009, ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... the rights in North America to its most advanced bite antibody candidate, blinatumomab, also known as ... a research program for the development of a new bite antibody for the treatment of hematological ... excited about the prospects for 2009. Our lead bite antibody program blinatumomab reported ...

Micromet to Present at the Cowen Health Care Conference on March 17, 2009

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors

... candidates to pivotal trials." "Micromet's bite antibodies have the potential to become the next ... and contributing to the development of its bite antibodies and other clinical stage product ... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ...

Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009

... antibody technology is based on its proprietary bite antibody platform, representing a new class of ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling

... binding to EpCAM. MT110, an EpCAM-specific bite antibody, is being tested in a phase 1 clinical ... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ...

Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG

... obtain a license to one of Micromet's preclinical bite antibodies against an undisclosed oncology ... to secure a one year option on a specific bite antibody. Bayer Schering Pharma may exercise ... Bayer Schering Pharma on the development of the bite antibody through the completion of phase 1 ...

Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

... 2 clinical trial of blinatumomab for ALL find the bite antibody was able to eliminate MRD. Six patients ... passcode: 39298646. About bite Antibodies BiTE(R) antibodies are ... to escape recognition by T cells. The use of bite antibodies that are specifically designed to ...

Micromet to Present at the RBC Capital Markets Healthcare Conference

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... psoriasis, or multiple sclerosis. Additional bite antibodies, targeting CEA, CD33, Her2, EGFR and ...

Micromet Added to NASDAQ Biotechnology Index

... antibody technology is based on its proprietary bite antibody platform, representing a new class of ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... psoriasis, or multiple sclerosis. Additional bite antibodies, targeting CEA, CD33, Her2, EGFR and ...

Micromet, Inc. Reports Third Quarter 2008 Financial Results

... antibody technology is based on its proprietary bite antibody platform, representing a new class of ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... psoriasis, or multiple sclerosis. Additional bite antibodies, targeting CEA, CD33, Her2, EGFR and ...

Micromet Closes $40 Million Private Equity Placement

... R&D Efforts and Clinical Trials Advancing the bite Therapeutic Antibody Platform BETHESDA, Md., ... our clinical antibody programs and to broaden our bite antibody pipeline." Under the terms of the ... of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies ...

Micromet Announces Definitive Agreement for $40 Million Private Equity Placement

... R&D Efforts and Clinical Trials Advancing the bite Therapeutic Antibody Platform BETHESDA, Md., ... of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies ... of our product candidates, the development of our bite antibody technology, the conduct, timing and ...

Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule

... of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies ... of AstraZeneca plc. MT110 is the second bite antibody in clinical trials, and is being ... of our product candidates, the development of our bite antibody technology, the conduct, timing and ...

Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer

... of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies ... of AstraZeneca plc. MT110 is the second bite antibody in clinical trials, and is being ... of our product candidates, the development of our bite antibody technology, the conduct, timing and ...

Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results

... in late stage lymphoma patients. The bite antibody could also clear the bone marrow and ... completed preclinical development for its second bite antibody MT110. MT110 binds to EpCAM, a cell ... 2007, we have made significant progress with our bite antibodies demonstrating strong clinical ...

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference

... Presentation on MCSP-specific bite Antibody Selected by AACR for Press ... target biology and therapeutic window for two new bite antibodies in pre-clinical development. bite antibodies are T cell recruiting antibodies ...

Scientists say sabercat bit like a pussycat

... called Finite Element Analysis (FEA) to test the bite force and feeding mechanics of the fearsome ... More recently, people have suggested that the bite was strong." Using the skull of a modern-day ... determined that Smilodon had a relatively weak bite - about one third as powerful as a lion of ...

Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results

... clinical trial for the treatment of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies that activate a patient's ... and intended utilization of our product candidates, the development of our bite antibody technology, the conduct, timing and results of future clinical ...

Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine

... About China's Veterinary Rabies Vaccine Market Rabies is a fatal infection of the central nervous system acquired through the bite of a rabid animal. The fatality rate of this infection is 100% when left untreated. The World Health Organization (WHO) recognizes rabies as ...

IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis

... has caused epidemics in India, Africa, Latin America and along the Mediterranean coast. Leishmania parasites are transmitted to humans through the bite of infected sandflies. Visceral leishmaniasis, the most severe form of the disease, causes fatal infections of internal organs, while the cutaneous ...

New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS

... them from re-circulating. Atrium formed a partnership with the University of Aberdeen and Rothamsted Research, who, having discovered why midges bite some people and not others, developed a more effective midge repellent naturally produced by humans. When looking for an efficient spray technology ...

Autonomy Meridio Enables Extract Technology to Enhance Capabilities in Compliance With Manufacturing Regulations

... (UK) +44(0)207-831-3113 edward.bridges@fd.com Tania Kempf Cohn & Wolfe (US) +1-650-281-7556 Tania_Kempf@sfo.cohnwolfe.com Clare Gayner bite Communications (UK) +44(0)20-8834-3454 Clare.Gayner@bitepr.com ...

Insulet Reports First Quarter 2008 Results

... Inc. and presented at the American Association for Cancer Research meeting in April exploring different routes of administration of its bite antibody MT110 for the treatment of cancer. * Insulet is an industry partner in a majority of the sites supporting the Juvenile Diabetes ...

MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research

... 8:00 a.m. - 12:00 p.m. in Exhibit Hall B-F. -- Bioavailability, Pharmacodynamic Activity, and Anti-Tumor Efficacy of the CD19/CD3-Specific bite Antibody MEDI-538 (MT103) Delivered Subcutaneously in Animal Models (Poster Session: Antibodies and Immunotherapy, abstract 2131, poster ...

AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights

... are liposomal amphotericin (Ambisome(R)) and Paromomycin. About leishmaniasis Leishmaniasis is an infectious disease transmitted by the bite of the phlebotomine sandfly. The cutaneous form of the disease normally produces skin ulcers on the exposed parts of the body such as the face, arms ...
Other Contents
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
(Date:12/19/2014)... 2014 Hands On Mobile Spa, has announced ... Spa On Wheels has been transformed into a utopia for ... world seems to disappear. The Virtual Tour showcases the beauty ... parties, corporate events and more. , The Virtual Tour shows ... which is actually an overhauled Winnebago. Marla Kaplan-Pelle, Director states ...
(Date:12/19/2014)... 19, 2014 Slone Partners ... personalized medicine, healthcare information technology, and laboratory testing ... of Chief Operating Officer. The announcement comes after ... by a strengthened presence in Boston and several ... lives and breathes the client experience," said Adam ...
(Date:12/19/2014)... Wilmington, VT (PRWEB) December 19, 2014 ... full-service private ski club in Southern Vermont’s Deerfield Valley, ... trail names inspired by classic rock songs. , ... the weekend with a private concert followed by a ... said, “The new trail names include: “I’m Alright” the ...
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... to moms who were exposed to high levels of air ... developing autism, a U.S. study suggests. Researchers found that ... and 2002, those exposed to the most air pollution during ... later developed autism. And exposure during the third trimester, specifically, ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... leg for at least 20 seconds you may be at ... on one leg may indicate that small strokes or tiny ... serious strokes is high, the investigators reported online Dec. 18 ... while standing on one leg, as well as problems walking, ...
Breaking Medicine News(10 mins):Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2
Other TagsOther Tags